New aspects of the pathogenesis of rosacea

Drug Discovery Today: Disease Mechanisms

Volumn 5, Issue 1, 2008, Pages

  Fimmel, Sabine ^a   Abdel Naser, Mohamed Badawy ^b,c   Kutzner, Heinz ^d   Kligman, Albert M ^e   Zouboulis, Christos C ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DESSAU MEDICAL CENTER   (Germany)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d Dermatopathologische Gemeinschaftspraxis   (Germany)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA INTERMEDIN; CALCITONIN GENE RELATED PEPTIDE; CORTICOTROPIN RELEASING FACTOR; CYCLOSPORIN A; INTERLEUKIN 18; NEUROPEPTIDE; PIMECROLIMUS; PROOPIOMELANOCORTIN; SUBSTANCE P; TACROLIMUS;

CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG TARGETING; ELASTOSIS; HUMAN; IMMUNE DEFICIENCY; INFLAMMATION; LYMPHOCYTIC INFILTRATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PULSED DYE LASER; REVIEW; ROSACEA; TELANGIECTASIA; ULTRAVIOLET IRRADIATION;

EID: 67349162107     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2008.04.010     Document Type: Review

References (59)

1. Powell F.C. Clinical practice. Rosacea. N. Engl. J. Med. 352 (2005) 793-803
2. National Rosacea Society (2006) What is rosacea? Available at http://www.rosacea.org. Accessed September 14, 2006
3. Berg M., and Liden S. An epidemiological study of rosacea. Acta Dermatol. Venereol. (Stockh.) 69 (1989) 419-423
4. Rosen T., and Stone M.S. Acne rosacea in blacks. J. Am. Acad. Dermatol. 17 (1987) 70-73
5. Abdel Naser, M.B. and Zouboulis, C.C. Rosacea and related disorders. In Treatment of Skin Diseases (Krieg, T., et al., eds), Springer (in press)
6. Wilkin J., et al. National Rosacea Society Expert Committee. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J. Am. Acad. Dermatol. 50 (2004) 907-912
7. Bamford J.T. Rosacea: current thoughts on origin. Semin. Cutan. Med. Surg. 20 (2001) 199-206
8. Plewig, G. and Kligman, A.M. (2000) Acne and Rosacea, pp. 433-475, Springer
9. Crawford G.H., et al. Rosacea: I. Etiology, pathogenesis, and subtype classification. J. Am. Acad. Dermatol. 51 (2004) 327-341
10. Slominski A., and Wortsman J. Neuroendocrinology of the skin. Endocr. Rev. 21 (2000) 457-487
11. Weinstock J.V., and Elliott D. The somatostatin immuno-regulatory circuit present at sites of chronic inflammation. Eur. J. Endocrinol. 143 (2000) S15-S19
12. Powell F.C., et al. Substance P and rosacea. J. Am. Acad. Dermatol. 28 (1993) 132-133
13. Lonne-Rahm S., et al. Laser treatment of rosacea: a pathoetiological study. Arch. Dermatol. 140 (2004) 1345-1349
14. Wollina U. Rhinophyma-unusual expression of simple-type keratins and S100A in sebocytes and abundance of VIP receptor-positive dermal cells. Histol. Histopathol. 11 (1996) 111-115
15. Kligman A.M. A personal critique on the state of knowledge of rosacea. Dermatology 208 (2004) 191-197
16. Murphy G.M. Ultraviolet light and rosacea. Cutis 74 (2004) 32-34
17. Yano K., et al. Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. Br. J. Dermatol. 152 (2005) 115-121
18. Smith J.R., et al. Expression of vascular endothelial growth factor and its receptors in rosacea. Br. J. Ophthalmol. 91 (2007) 226-229
19. Valverde P., et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat. Genet. 11 (1995) 328-330
20. Aubin F. Mechanisms involved in ultraviolet light-induced immunosuppression. Eur. J. Dermatol. 13 (2003) 515-523
21. Lachgar S., et al. Inhibitory effects of retinoids on vascular endothelial growth factor production by cultured human skin keratinocytes. Dermatology 199 (1999) 25-27
22. Kosmadaki G., et al. UV induces VEGF through a TNF-alpha independent pathway. FASEB J. 17 (2003) 446-448
23. Howell B.G., et al. Microarray analysis of UVB-regulated genes in keratinocytes: downregulation of angiogenesis inhibitor thrombospondin-1. J. Dermatol. Sci. 34 (2004) 185-194
24. McKenzie R.C. Ultraviolet radiation B (UVB)-induction of leukaemia inhibitory factor (LIF) in human keratinocytes. Photodermatol. Photoimmunol. Photomed. 17 (2001) 284-285
25. Buckman S.Y., et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 19 (1998) 723-729
26. Motley R.J., et al. The significance of telangiectasia in rosacea. In: Marks R., and Plewig G. (Eds). Acne and Related Disorders (1989), Martin Dunitz 339-344
27. Helm K.F., et al. A clinical and histopathologic study of granulomatous rosacea. J. Am. Acad. Dermatol. 25 (1991) 1038-1043
28. Nakamuro K., and Johnson W.C. Ultraviolet light induced connective tissue changes in rat skin: a histologic and histochemical study. J. Invest. Dermatol. 51 (1968) 194-198
29. Neumann E., and Fritz A. Capillaropathy and capillaroneogenesis in the pathogenesis of rosacea. Int. J. Dermatol. 37 (1998) 263-266
30. Ramelet A., and Perroulaz G. Rosacée: étude histopathologique de 75 cas. Ann. Dermatol. Vénéréol. 115 (1988) 801-806
31. Ozkaya-Bayazit E., and Buyukbabani N. Annular elastolytic giant cell granuloma sparing a burn scar and successful treatment with chloroquine. Br. J. Dermatol. 140 (1999) 525-530
32. Al-Hoqail I.A., and Al-Ghamdi A.M. Actinic granuloma is a unique and distinct entity. Am. J. Dermatopathol. 24 (2002) 209-212
33. Aroni K., et al. Rosacea: a clinicopathological approach. Dermatology 209 (2004) 177-182
34. de Wied D. Peptide hormones and neuropeptides: birds of a feather. Trends Neurosci. 23 (2000) 113-114
35. Seiffert K., and Granstein R.D. Neuropeptides and neuroendocrine hormones in ultraviolet radiation-induced immunosuppression. Methods 28 (2002) 97-103
36. Legat F.J., et al. The role of calcitonin gene-related peptide in cutaneous immunosuppression induced by repeated subinflammatory ultraviolet irradiation exposure. Exp. Dermatol. 13 (2004) 242-250
37. Sleijffers A., et al. Ultraviolet B radiation induces upregulation of calcitonin gene-related peptide levels in human Finn chamber skin samples. J. Photochem. Photobiol. B 69 (2003) 149-152
38. Legat F.J., et al. Repeated subinflammatory ultraviolet B irradiation increases substance P and calcitonin gene-related peptide content and augments mustard oil-induced neurogenic inflammation in the skin of rats. Neurosci. Lett. 329 (2002) 309-313
39. Wilkins B.W., et al. Mechanisms of vasoactive intestinal peptide-mediated vasodilation in human skin. J. Appl. Physiol. 97 (2004) 1291-1298
40. Pierard-Franchimont C., et al. Incidental control of rosacea by somatostatin. Dermatology 206 (2003) 249-251
41. Grammatopoulos D.K., and Chrousos G.P. Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol. Metab. 13 (2002) 436-444
42. Slominski A., et al. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol. Rev. 80 (2000) 979-1020
43. Zouboulis C.C., et al. Corticotropin-releasing hormone: an autocrine hormone that promotes lipogenesis in human sebocytes. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 7148-7153
44. Slominski A., et al. CRH stimulation of corticosteroids production in melanocytes is mediated by ACTH. Am. J. Physiol. Endocrinol. Metab. 288 (2005) 701-706
45. Toyoda M., et al. Neuropeptides and sebaceous glands. Eur. J. Dermatol. 12 (2002) 422-427
46. Flint M.S., et al. Restraint stress and corticotropin releasing hormone modulation of murine cutaneous POMC mRNA. Stress 6 (2003) 59-62
47. Crompton R., et al. Corticotropin-releasing hormone causes vasodilation in human skin via mast cell-dependent pathways. J. Clin. Endocrinol. Metab. 88 (2003) 5427-5432
48. Theoharides T.C., et al. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol. Sci. 25 (2004) 563-568
49. Lytinas M., et al. Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists. Int. Arch. Allergy Immunol. 130 (2003) 224-231
50. Park H.J., et al. Corticotropin-releasing hormone (CRH) downregulates interleukin-18 expression in human HaCaT keratinocytes by activation of p38 mitogen-activated protein kinase (MAPK) pathway. J. Invest. Dermatol. 124 (2005) 751-755
51. Zbytek B., et al. Corticotropin-releasing hormone stimulates NF-kappaB in human epidermal keratinocytes. J. Endocrinol. 181 (2004) R1-R7
52. Krause K., et al. Corticotropin-releasing hormone skin signalling is receptor-mediated and is predominant in the sebaceous glands. Horm. Metab. Res. 39 (2007) 166-170
53. Marks R. The enigma of rosacea. J. Dermatolog. Treat. 18 (2007) 326-328
54. Aroni K., et al. A study of the pathogenesis of rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. Arch. Dermatol. Res. 300 (2008) 125-131
55. Pisarchik A., et al. A novel microarray to evaluate stress-related genes in skin: effect of ultraviolet light radiation. Gene 341 (2004) 199-207
56. Bamford J.T., et al. Tacrolimus effect on rosacea. J. Am. Acad. Dermatol. 50 (2004) 107-108
57. Weissenbacher S., et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br. J. Dermatol. 156 (2007) 728-732
58. Shanler S.D., and Ondo A.L. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch. Dermatol. 143 (2007) 1369-1371
59. Del Rosso J.Q. Recently approved systemic therapies for acne vulgaris and rosacea. Cutis 80 (2007) 113-120